{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092265","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.822903+00:00","generated_at":"2026-05-31T11:39:39.439313+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program","bullets":["Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.","Cash, equivalents and marketable securities $226.1M at June 30; projected runway into 2026.","Open-label extension study all 7 sites activated; interim data planned Q4 2024.","FDA selected nomlabofusp for START pilot to accelerate development; BLA submission targeted 2H 2025.","Planning PK run-in study in adolescents by year-end 2024; global confirmatory study by mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092265","json":"https://secwatch.observer/filing/0000950170-24-092265.json","markdown":"https://secwatch.observer/filing/0000950170-24-092265.md","text":"https://secwatch.observer/filing/0000950170-24-092265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/0000950170-24-092265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/lrmr-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:39:39.439313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}